Biovie is trading 5% down at $1.69 after September 15 results showed its Phase 2 ADDRESS-LC trial missed statistical significance across all 22 endpoints in the full 203-patient population.
- No fresh company-specific catalyst was identified for September 18, 2026.
- Positive subgroup findings and a September 18 promotional interview announcement have not offset investor concerns.
- Biotech is broadly higher, so Biovie is underperforming its sector rather than simply tracking industry sentiment.